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Traumatic brain injury (TBI) is the principal cause of death and disability in children and
young adults. Clinical and preclinical research efforts have been carried out to understand
the acute, life-threatening pathophysiological events happening after TBI. In the past few
years, however, it was recognized that TBI causes significant morbidity weeks, months,
or years after the initial injury, thereby contributing substantially to the overall burden of TBI
and the decrease of life expectancy in these patients. Long-lasting sequels of TBI include
cognitive decline/dementia, sensory-motor dysfunction, and psychiatric disorders, and
most important for patients is the need for socio-economic rehabilitation affecting their
quality of life. Cerebrovascular alterations have been described during the first week after
TBI for direct consequence development of neuroinflammatory process in relation to brain
edema. Within the brain–immune interactions, the complement system, which is a family
of blood and cell surface proteins, participates in the pathophysiology process. In fact,
the complement system is part of the primary defense and clearance component of
innate and adaptive immune response. In this review, the complement activation after
TBI will be described in relation to the activation of the microglia and astrocytes as well as
the blood–brain barrier dysfunction during the first week after the injury. Considering the
neuroinflammatory activity as a causal element of neurological handicaps, some major
parallel lines of complement activity in multiple sclerosis and Alzheimer pathologies with
regard to cognitive impairment will be discussed for chronic TBI. A better understanding
of the role of complement activation could facilitate the development of new therapeutic
approaches for TBI.
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TRAUMATIC BRAIN INJURY
Traumatic brain injury (TBI) is a consequence of a direct or indirect external mechanical
impact on the brain inducing the disruption of the normal structure and function of the
brain. Despite its simple mechanical definition, TBI is a very complex and heterogeneous
injury with various severities graded in clinic. The severity of TBI is predicated on alteration
of consciousness, organized according to the Glasgow Coma Scale (GCS) for assessment of
neurological function and neuroimaging as mild, moderate, or severe (Maas et al., 2008).
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TBI is a major burden worldwide, and in the United States, it
represents more than 30% of all injury-related deaths (Faul et al.,
2010). In Europe, it is about 75,000 deaths each year (Maas et al.,
2015), and it affects all ages. It is important to underline that
pediatric and elderly populations are more vulnerable than adults
(Faul et al., 2010). Therefore, TBI has an economic toll on the
society that includes medical expenses and losses of productivity
(Corso et al., 2006; Gustavsson et al., 2011). A widespread
research on TBI pathophysiology is still sparse compared to
other brain diseases such as Alzheimer’s disease (AD) and the
progressive chronicity of multiple sclerosis (MS).
Pathophysiology following TBI is grouped into the following:
(1) The primary acute event is the mechanical injury that
can give extracranial and intracranial complications like
epidural hematoma, subarachnoid hemorrhage, or hypoxia.
Thus, TBI is particularly heterogeneous depending on the
primary injury severity, location, and the age and sex of
the patient. Important in the TBI pathogenesis is that the
functional outcomes may deteriorate over time after initial
admission of the patient (Baethmann et al., 1988). For
example, the patient can communicate early after TBI and
then worsen with loss of consciousness, with an early small
contusion that becomes a much larger injury the day after.
This evolution is due to the secondary injury events (Plesnila,
2016). (2) The secondary injury cascade includes the following
landmarks: glutamatergic excitotoxicity, calcium overload,
vascular dysfunction, and inflammation/neuroinflammation.
Inflammation/neuroinflammation can last for several months
and could contribute to chronic TBI (Plesnila, 2016). The
pattern of “chronic brain disease” has been leading the concept
of accelerating of brain aging post-TBI (Johnson et al., 2010;
Pop and Badaut, 2011; Smith et al., 2013). Patients can present
long-lasting behavioral dysfunctions including some psychiatric
disorders after TBI (Smith et al., 2013). Very recently, a
nationwide population cohort study was done in Denmark to
monitor individuals who had TBI from 1977 to 2013. Over the
study period, 4.7% of recruited people had at least one TBI,
and about 112,218 (85.0%) of 132,093 individuals had a mild
TBI for their first TBI diagnosis; those people were 24% more
likely to develop dementia than those without a history of TBI.
Additionally, the younger the person was at the time of the
injury, the higher the risk of dementia development over time
(Fann et al., 2018).
Several animal models have been developed in order to extend
our understanding of the cellular and molecular mechanisms in
post-TBI secondary injuries (Prins and Hovda, 2003; Petraglia
et al., 2014). Having a wide variety of preclinical models is a
good sketch to mimic the heterogeneity in human TBI. However,
it is important to highlight that the definition of the degree of
TBI severity differs between animal models, and it is difficult
to compare findings between models (Badaut et al., 2019).
Sometimes, it is challenging to make the translation with clinical
severities. The molecular and cellular mechanisms of secondary
injuries are dependent on injury severity and brain location. The
post-TBI outcome is more severe for younger patients; therefore,
it is important to consider the age of the animal in the preclinical
models (McMillan and Teasdale, 2007; Himanen et al., 2011; Pop
and Badaut, 2011). In fact, neuroinflammation/inflammation
response will vary in function of the location and severity
of the impact as well as the age of the animal. The review
focuses on some of the cerebrovascular alterations and the
importance of the inflammation through the exploration of the
complement system as a new potential mechanism. Actually,
the role of the complement pathway in TBI pathogenesis is not
yet well-understood.
NEUROVASCULATURE IMPAIRMENT
POST-TBI
The neurovascular unit (NVU) is composed of neurons, a
vascular tree with endothelial cells, smooth muscle cells,
pericytes, astrocytes, and microglia (Zhang et al., 2012). Immune
cells have been included as part of this physiological unit (Zhang
et al., 2012). Cognitive impairments in AD as well as in healthy
aging have been paralleled with NVU alterations (Iadecola,
2004; Raz et al., 2016). Similarly, NVU alteration is a typical
landmark of the secondary injuries after TBI with, for example,
a decrease of blood–brain perfusion with consequences on the
good operation of the neurons (Pop and Badaut, 2011; Jullienne
et al., 2016). In fact, preclinical TBI models unveil blood–brain
barrier (BBB) disruption, hemorrhage, and cerebral blood flow
alterations with hypo-perfusion, which are illustrations of the
NVU alterations (Golding, 2002; DeWitt and Prough, 2003;
Pop and Badaut, 2011). Cerebrovascular dysfunction has been
described for almost two decades as a poor prognostic outcome.
In fact, early decrease of the cerebral blood flow (CBF) post-
injury induces hypoxic events in the brain tissue that directly
contribute to the loss of neurons. In addition, the changes in
BBB permeability play a role in edema formation with disruption
of brain homeostasis. It exacerbates the cascade of secondary
injury events including excitotoxicity (glutamate release and
resulting higher metabolic demand) and inflammation (with the
complement pathway, see below). TBI is a chronic brain disorder
withmolecular changes at the BBB several months after the initial
injury (Jullienne et al., 2016). As it has been suggested in AD, the
long-term alterations at the blood–brain interface could therefore
be associated with premature aging of the brain after TBI (Pop
and Badaut, 2011; Keightley et al., 2014; Jullienne et al., 2016).
Brain Perfusion Alterations
Early decrease of CBF is a landmark of the pathophysiology
post-TBI and its recovery represents a prognostic factor for
outcome post-TBI (Bouma et al., 1991, 1992; DeWitt and Prough,
2003). Preclinical models appropriately reproduce CBF changes
observed in clinic. Decreased CBF is observed after TBI using
controlled cortical impact (CCI) and lateral fluid percussion
(LFP) injury models and it is described up to 8 months after
injury in adult rats (Bouma et al., 1991; Bryan et al., 1995;
Plesnila et al., 2003; Hayward et al., 2010), which probably
feeds the inflammatory process. Even for mild TBI, a decrease
of CBF has also been described (Villapol et al., 2014; Long
et al., 2015). In a mild CCI model, the reduction of CBF was
described with restoration at 30 days post-TBI in young adult
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mice (Villapol et al., 2015). Importantly, hypo-perfusion adds to
the development of the secondary injuries after TBI by decreasing
glucose and oxygen delivery. Moreover, an ischemic event could
be aggravated by the presence of cell hyper-metabolism during
the first 6 h after concussion in rats (Yoshino et al., 1991).
Consequently, decreased CBF and hyper-metabolism occurring
early after TBI result in a mismatch between demand and supply,
known as uncoupling of CBF and glucose metabolism, with
direct consequence and aggravation of the secondary injuries
and directly feeding the inflammation and neuroinflammation
process. At the time, dysfunction in vascular perfusion is
paralleled with BBB hyper-permeability and edema process.
BBB Dysfunction Post-TBI
The presence of hemorrhage is a marker of acute vascular
dysfunction, and it is frequently observed in moderate and severe
TBI. BBB and cerebral blood vessel alterations are frequently
shadowed by edema formation with dramatic consequences
on morbidity and mortality because it induces intracranial
hypertension and contributes to the vicious cycle of the
secondary injury cascade (Unterberg et al., 2004). Even for mild
TBI characterized by the absence of major bleeding, the BBB
structure can be damaged or altered during the acute period after
the injury. Very importantly, the BBB dysfunction is not only an
acute event; it could also be observed several months and years
after the traumatic event in human post-mortem tissue (Hay
et al., 2015) and in preclinical models (Pop et al., 2013; Jullienne
et al., 2014).
The consequences of primary injury on the BBB properties
significantly differ according to the age, the type, and the severity
of the lesion. The “opening” of the BBB can be observed as
early as 3min after injury in a model of concussion (Povlishock
et al., 1978). The “opening” of BBB can be characterized with
the presence of two types of lesions on the luminal surface
of pial arterioles: crater-shaped indentations and dome-shaped
projections of the endothelial cell surface, suggesting necrotic
cells (Wei et al., 1980). The tight junction protein complex
is potentially altered after TBI. In fact, pial, and intracerebral
blood vessels demonstrate decreased claudin-5 and occludin
expressions early after injury (Nag et al., 2007). Similar changes
in tight junction protein complex have been described in
rodent models of mild TBI induced by blast shock waves, with
specifically decreased expression in occludin, claudin-5, and
zonula occludens protein-1 at 6 h and 24 h post-TBI (Abdul-
Muneer et al., 2013). The changes in tight junction proteins
have been paralleled with an increase of immunoglobulin G
extravasation from 5min to 48 h post-injury (Yeoh et al., 2013;
Shetty et al., 2014). However, it is important to underline
that tight junction complexes appear intact under electron
microscopy during the first hours after a mild TBI; then,
the expression of the tight junction protein is altered (Rafols
et al., 2007). Therefore, the changes in expression of the tight
junction proteins and increased IgG extravasation are not directly
linked with physical rupture of the tight junctions in electron
microscopy (Knowland et al., 2014; Haley and Lawrence, 2017).
Similarly, IgG extravasation is increased close to the site of
impact and surrounding tissue in the absence of a direct relation
with changes in claudin-5 expression in a model of juvenile
CCI (Pop and Badaut, 2011; Badaut et al., 2015). Similarly, IgG
extravasation has been observed in the corpus callosum at 24 h
after mild closed head injury, suggesting BBB hyper-permeability
even for mild injury (Rodriguez-Grande et al., 2018).
Changes of expression of the tight junction proteins
are accompanied by up-regulation of various matrix
metalloproteases (MMPs), which have been involved in BBB
alteration. In fact, MMP-9 and MMP-2 increase acutely after
TBI in rodents (Wang et al., 2000; Zhang et al., 2010). MMP-3
activity is increased chronically after TBI and possibly plays a
role in synaptic remodeling (Zhang et al., 2010). Up-regulation of
MMPs alters proteins of the extracellular matrix and participates
in BBB alteration and neurovascular unit dysfunction.
In summary, it is important to highlight that neurovascular
unit disturbance, encompassing BBB and blood flow changes,
fuels the inflammation and neuroinflammation process.
Astrogliosis, Neuroinflammation, and
Consequences on Blood Perfusion and
BBB
Astrocyte endfeet wrap the blood vessels and they play a
key role in BBB properties in collaboration with pericytes
(Zhang et al., 2012). Astrocytes become “reactive” and proliferate
to form a glial scar in various severe brain injury models
(Burda and Sofroniew, 2014). Depending on the timeline of
the pathological process after injury, astrogliosis can be both
beneficial and detrimental to the brain tissue adjacent to the
lesion (Sofroniew, 2009). Astrocytes have various physiological
functions such as providing energy substrates for neurons,
regulating ion and neurotransmitter homeostasis, participating
in synapse development and transmission, and regulation of
CBF. Then, transformation of astrocyte in “reactive astrocyte”
can have a direct and weighty impact on the brain functions
on the post-injury outcomes (Sofroniew and Vinters, 2010).
Astrocytes are among the first responder brain cells to TBI,
and the mechanical forces of the primary injury trigger reactive
astrocyte or astrogliosis (Burda et al., 2016). In fact, stretch
injury or shear stress involves a rapid calcium influx in the
astrocytes (Rzigalinski et al., 1998; Maneshi et al., 2015), by
potential activation of astrocytic mechano-receptive channels
(Burda et al., 2016). In parallel, activation of the astrocyte
potentially contributes to the release of vasoactive substances
(Howarth, 2014). In fact, release of isoprostanes (Hoffman et al.,
1997, 2000) and endothelin 1 (Ostrow et al., 2000), powerful
vasoconstrictors, have been described to increase after TBI in
preclinical models (Petrov and Rafols, 2001; Armstead and
Kreipke, 2011; Armstead and Raghupathi, 2011). Then, any
changes in the calcium concentration within astrocytes could
have a direct or indirect consequence on the regulation of CBF
and perfusion post-injury. Then, calcium changes in astrocytes
could contribute to the NVU dysfunction post-TBI with the
increase of vasoconstrictor molecules.
Astrocytes play an important role in the integrity of the BBB
(Abbott et al., 2006). Cytokines and inflammatory mediators
are released by the astrocytes after injury with consequences
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on BBB properties (Chodobski et al., 2011; Sofroniew, 2014).
For example, chemokines (Chodobski et al., 2011) and three
isoforms of transforming growth factor–β (TGF- β) (Constam
et al., 1992), potentially released by the astrocytes, have been
implicated the BBB alterations after TBI (Shen et al., 2011). Very
interestingly, increased TGF-β expression has been observed in
patients with severe TBI where it parallels BBB dysfunction
(Morganti-Kossmann et al., 1999). As already discussed, MMPs
disturb the structure of the BBB after TBI and they are extensively
produced by reactive astrocytes (Chen and Swanson, 2003).
In the vicinity of the perivascular astrocyte endfoot, the water
channel aquaporin 4 expression is altered after TBI, which is
related to the formation of cerebral edema (Badaut et al., 2014;
Gatto et al., 2015; Zhang et al., 2015). Increased aquaporin
expression associated to edema brain formation event is also
described in earlier stages of several neurodegenerative diseases
(Sun et al., 2016; Yang et al., 2016; Gatto et al., 2018). There is
a correlation between the level of aquaporin 4 expression and
disruption of BBB (Fukuda and Badaut, 2012). The astrocyte
endfeet play a critical role in the BBB integrity, and very
interestingly, the physical interaction between astrocyte endfeet
and the brain vasculature can also be altered after TBI (Villapol
et al., 2014), with a direct contribution to the vascular dysfunction
after injury.
Altogether, astrocyte phenotypic transformation can feed
forward the brain-vascular pathology observed after TBI in
relation to neuroinflammation and the complement pathway. In
addition, the neurodegeneration proposed after TBI could be a
result of astrocyte activation and chronic inflammation (Faden
and Loane, 2015). Interestingly, astrocyte plays a potential role
in immune response in the brain with expression of the specific
receptors to complement proteins (see part 3). Therefore, it may
be important to consider the contribution of reactive astrocytes
into the long-term consequences of vascular dysfunction and a
target of the activation of the complement pathway. This pathway
could represent a new avenue for drug development targeting
the NVU.
GENERAL DESCRIPTION OF THE
COMPLEMENT PATHWAY
The complement system is part of an innate and adaptive
immune response after infection acting as a primary defense and
mechanism of clearance in order to preserve the organ against
pathogens. It includes a wide collection of blood and cell surface
proteins (C3, C5, CFB, CFD, CFH, C1q, etc.), whose activation
results in a self-amplifying cascade of proteolytic reactions
(Walport, 2001). Most of the plasmatic complement proteins
(90%) are produced by the hepatocytes in the liver (C3, C5,
CFB, CFH), released in the bloodstream to circulate as inactive
forms. However, a local expression of complement proteins is
also observed in cells (microglia/macrophages/astrocytes and
neuronal cells) in the brain and the eye, mainly for C3 and its
cleavage regulators (CFH and CFB).
The complement system is a key molecular pathway in
various cellular and molecular activities, ranging from cell lysis
to increase in the local inflammatory response. The complement
activation is composed of three main pathways: classical, lectin,
and alternate. They converge to the common effector pathway
by forming the membrane attack complex (MAC) as illustrated
in Figure 1.
The Classical Pathway
The classical pathway activation is antibody-dependent. It
happens when the complement protein C1 complex, formed
by C1q, C1r, and C1s proteins, interacts with antigen–IgM or
aggregated antigen–IgG complex, or is antibody-independent. It
also happens when poly-anions (e.g., heparin, protamine, DNA
and RNA from apoptotic cells), gram-negative bacteria, or bound
C-reactive protein reacts directly with the C1 complex. Once
the C1 complex is activated, then C1s cleave C4 and C2 into
C4a/C4b and C2a/C2b, respectively, and forms the C3 convertase
of the classical pathway (C4b2a). C4b2a cleaves C3 into C3a
and C3b fragments. The classical pathway is regulated by C1
inhibitor (C1-INH).
The Lectin Pathway
The lectin pathway is activated when mannose-binding lectin
(MBL), a serum protein, binds to mannose or fructose groups on
bacterial cell walls, yeast walls, or viruses, independently of the
antibody complex. The lectin pathway shares similarities with the
classical pathway.
The Alternative Pathway
The alternative pathway is activated after cleavage of a
small amount of complement compound C3 caused by
microbial cell surfaces or immunoglobulin. This pathway
is functionally present in physiological situation, with a
spontaneous (hydrolysis) cleavage of C3 to C3a/C3b. The
C3b product is rapidly inactivated by its binding to proteins
complement factor H (CFH) and associated with complement
factor I (CFI) as a co-factor, and then its opsonization functions
(tagging pathogens, immune complexes apoptotic cells for
phagocytosis) are aborted. After injury, C3b product binds
to complement factor B (CFB) and its co-factor complement
factor D (CFD) to form a molecular complex “C3bBb,” called
C3 convertase complex, which acts on additional C3 to form
more C3b and C3a products (Figure 1). This function of C3b
contributes to a positive feedback loop and amplifies a first C3
cleavage that is induced by either the classical pathway or both
classical and alternative pathways, in order to produce high-level
C3b and C3a proteins. It is important to highlight that each
complement pathway (classical, lectin, and alternative pathways)
activation ends up into the cleavage of C3.
Complement Cleavage Products Functions
Once activated, the complement pathway produces a high
concentration of anaphylactic C3a/C5a and opsin C3b proteins
(Figure 1). The receptors of these complement proteins
(C3aR, C5aR, and CD11b, respectively) are expressed on cell
membranes in various cerebral cell types such as endothelial
cells, microglia/macrophage cells, and astrocytes. The wide
distribution of the complement receptors underlines the variety
of cellular functions to this system. Importantly, the complement
systemmakes the link between the innate and acquired immunity
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FIGURE 1 | Schematic representation of complement activation pathways: The complement system is composed of three pathways (classical, lectin, and alternative
pathway) that involve a collection of blood and cell surface proteins to eliminate pathogens from organism or damaged cells. This system consists of a series of
proteins that interact with one another in a highly regulated manner. The classical pathway helps antibodies and phagocytic cells to clear pathogens or damaged cells.
The lectin pathway is activated when MBL binds to mannose residues on the pathogen surface. This pathway is very similar to the classical pathway. The alternative
pathway is an important part of innate immune system in which proteins cleave one another to form enzymatic complex able to initiate amplification of further
cleavages and finally promotes inflammation by production of anaphylactic fragments. The final product of each activated complement pathway is the formation of the
MAC in the target cell membrane. Once activated, the complement system has several major functions: lysis of pathogens or damaged cells, activation of
inflammation, opsonization, and immune clearance.
by (a) enhancing antibody response and immunologic memory,
(b) lysing the pathogens, and (c) clearing immune complexes
and apoptotic cells.
The anaphylactic C3a molecule has a remote result because it
diffuses away to play the role of an inflammation and chemotactic
factor. In contrast, the produced C3b binds to the C3 convertase
complex (C3bBb) to form a C5 convertase complex (C3bBbC3b).
The C5 convertase complex is located in the cell membrane or in
the bloodstream and cleaves complement 5 (C5) into C5b and
C5a fragments. Similarly to C3a, the C5a product is described
in the bloodstream to act remotely as an anaphylactic protein
inducing a general inflammatory reaction. In contrast, C5b
initiates the MAC in the cell membrane (Figure 1). Sequentially,
C5b interacts successively with C6, C7, and C8 complement
proteins, and finally with a number of C9 complement proteins
to form MAC. Importantly, MAC is organized in a circle with, in
its center, a pore that produces a hole in the cell membrane. High
concentration of MAC induces lysis of the foreign cell (such as
microbes or bacteria) or apoptosis (of host cell).
Very interestingly, MAC has been found to contribute to
secondary damages in various preclinical models of human brain
diseases (Leinhase et al., 2006; Stahel et al., 2009; Fluiter et al.,
2014; Ruseva et al., 2015). However, depending on the level
of expression of MAC, opposite physiological responses can be
observed. In fact, a low level of the MAC (C5b9) complex on
the cell surface promotes cell-cycle progression instead of cell
lysis or apoptosis (Fosbrink et al., 2005). The role of MAC in
cell-cycle progression is due to the transactivation of receptor
tyrosine kinases, a regulator of cytosolic free Ca2+ concentration
(Cybulsky et al., 1999), and activation of protein kinase C and
cytosolic phospholipase A2-α (Cybulsky et al., 1995; Panesar
et al., 1997).
It is important to have a fine-tuned regulation of MAC
formation with a full panel of specific inhibitor proteins. Many
of the complement regulator proteins are found in the blood
plasma and on the cell membranes, and among them, CFH acts
on the activity of the upstream C3 convertase complex (C3bBb)
in the blood and on the cell surface. CFH removes “Bb fragment”
from the C3 convertase enzymatic complex and inactivates C3
cleavage by competition with CFB for binding C3b; it stops the
main amplification loop of the alternative complement pathways
(Figure 1). Downstream, CD55 (or DAF: decay accelerating
factor), CD46 (or MCP: membrane cofactor protein), and CD59
(known as protectin) have also been described as inhibitors of
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MAC formation in the cell membrane for both classical and
alternative complement pathways (Figure 1).
INVOLVEMENT OF COMPLEMENT
PATHWAY IN TBI PATHOPHYSIOLOGY
The secondary injury events post-TBI include inflammatory
mechanisms with early activation of the innate immune
system, and then the chronic inflammation post-injury possibly
contributes to the progressive neurodegenerative process
(Francis et al., 2003; Schmidt et al., 2005; Stahel and Barnum,
2006).
The complement pathway represents a key element in the
inflammatory response, and it contributes to neuronal cell death,
edema, and infiltration of inflammatory cells after injury using
rodent models of moderate and severe TBI (Kaczorowski et al.,
1995; Ruseva et al., 2015; Rich et al., 2016). Involvement of
the complement pathway observed in rodent TBI models has
been confirmed with up-regulation of CFB (Kossmann et al.,
1997), C3, C1q, and C4 (Stahel et al., 1998), and increase of
soluble terminal complement complex C5b9 has been detected
in ventricular cerebrospinal fluid (CSF) of severe TBI patients for
up to 10 days after trauma, possibly due to the alteration of the
BBB integrity (Stahel et al., 2001). CSF increase of complement
proteins is paralleled by higher concentration of complement
proteins in blood plasma of TBI patients (Manek et al., 2018).
Expression of complement protein C3 and C9 has been described
up to 6 months post-injury (Bao et al., 2018) in patients,
suggesting a continuous complement pathway activation in the
chronic TBI. Very interestingly, similar observations have been
found in various preclinical rodent models, with higher levels
of C9 and CFB in serum of rat during the first days after TBI
(Thelin et al., 2018). Deposits of C3 have also been described
in the peri-lesion tissue, while C9 protein has been reported
in damaged neurons after cortical contusion in the adult rat
(Bellander et al., 1996). Thus, a similar change in activation of
the complement pathway has been described in clinical and in
preclinical rodent models.
As presented above, C3 protein is common to the three
complement pathways. In this line with the complement
pathway inhibition in TBI, C3−/− mice exhibit less brain
edema and microglia activation/infiltration compared to WT
after TBI, suggesting a role of the complement pathways in
the secondary injury cascade (Sewell et al., 2004; Yang et al.,
2006) and inhibition of C3 could be a therapeutic strategy.
Interestingly, severe TBI swine resuscitation with valproic acid
(a histone deacetylase inhibitor) induces a down-regulation of
the complement system activation, resulting in a significant
decrease of lesion size after resuscitation (Dekker et al., 2014a,b;
Bambakidis et al., 2016). Similarly, inhibition of MAC has
been proposed to be protective. In fact, over-exuberant MAC
formation contributes to neuronal cell death after severe TBI
injury in mice lacking CD59, an inhibitor of MAC formation
on the membrane cells (Figure 1) (Stahel et al., 2009). The
inhibition of MAC formation using C6 antisense oligonucleotide
or an inhibitor of C5 convertase complex reduces not only MAC
deposition but also accumulation of microglia/macrophages,
neuronal death, and axonal loss and enhances neurologic
performances as compared to the placebo-treated TBI group
(Fluiter et al., 2014).
The current paradigm is that MAC formation is
predominantly implicated in development of post-TBI process
neuropathology and neuroinflammation, but it is not excluded
that C3 cleavage inhibition could prevent inflammation and/or
cell death. Then, C3 and MAC would be good therapeutic
targets to reduce TBI damage. Studies show that inhibition
of C3 cleavage reduces post-injury of microglial and astrocyte
activations, C3 deposits, and the extent of neuron cell death, and
then triggers improvements in cognitive and functional recovery
(Rich et al., 2016; Alawieh et al., 2018). It demonstrates a critical
role of the complement system and mainly of the alternative
pathway in the TBI neuropathology process.
Targeted deletion of cfb gene expression, the activator of
alternate complement pathway by activation of C3 convertase, in
transgenic mice clearly reveals a significant decrease of neuronal
cell death post-TBI (Leinhase et al., 2006). In support to these
results in transgenic mice, inhibition of the CFB by injection
of anti-CFB monoclonal antibody attenuates both inflammation
and cell death in TBI animals (Leinhase et al., 2007), confirming
a key role of the alternative complement system in TBI.
Both the classical and lectin pathways have also been
assessed in preclinical TBI models and human studies: (1)
C1-inhibitor injection after TBI mitigates motor deficits,
cognitive dysfunction, and contusion volumes (Longhi
et al., 2009), arguing for a role of the classical complement
pathway in TBI secondary injuries. (2) Activation of the
lectin complement pathway has been shown to be involved
in secondary ischemic/inflammatory injury after severe TBI
along with an increase of MBL protein in plasma of patients
at 48 h post-injury (Osthoff et al., 2017). However, there is no
correlation between lectin complement pathway activation and
mortality/consciousness after severe TBI (Osthoff et al., 2017).
In human and mice, MBL is expressed in the injured cortex from
30min and persists up to 1 week post-TBI (Longhi et al., 2014).
The inactivation of the lectin complement pathway induces a
decrease of cortical cell death (Longhi et al., 2014), arguing that
this deletion has a protective effect in TBI damages. Until now,
no specific pharmacological compound has been found to limit
TBI damages, but targeting complement pathway would be a
novel therapeutic way.
CHRONIC TBI AND
NEURODEGENERATIVE LANDMARKS
Neurodegenerative Landmarks After TBI
Brain vasculature alterations and inflammatory processes
implicating complement pathways are very likely hand in hand
in the early secondary events post-injury. Several works clearly
indicate that TBI is a chronic brain disorder with development
of neurodegenerative disease landmarks such as accumulation of
the amyloid-β (Aβ) (Johnson et al., 2010; Pop and Badaut, 2011;
Pop et al., 2013). We and other groups have shown changes in the
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brain vasculature and their involvement in functional outcome
after TBI, with BBB dysfunctions several months and years after
the injury (Pop et al., 2013; Hay et al., 2015). We previously
described increase of claudin-5 expression in large blood vessels,
decrease of the eﬄux pump P-glycoprotein (P-gp), and increase
of the perivascular matrix proteins perlecan and fibronectin up
to 6 months post-injury in a juvenile TBI model (Pop et al.,
2013; Jullienne et al., 2014). The matrix changes observed up to 6
months after juvenile TBI (Jullienne et al., 2014) have also been
described in AD patients (Lepelletier et al., 2017). Changes in
the matrix properties possibly participate in neurodegenerative
processes by leading to the accumulation of Aβ, decreasing its
clearance and its perivascular drainage (Pop et al., 2013; Jullienne
et al., 2014). P-gp has been suggested to be a key player in Aβ
clearance from the brain parenchyma. P-gp knock-out models
have increased Aβ deposition after injection of Aβ in the brain
compared to the wild type (Cirrito et al., 2005). Moreover, P-gp
expression is decreased on endothelial cells in aged human and
AD brains as well as in aged rodents (Silverberg et al., 2010).
In addition to the vascular dysfunction, the presence of Aβ
deposition could contribute to amplify the pathophysiology
with activation of the complement pathways around the Aβ
deposition, and the vicious cycle of chronic inflammation would
accelerate the brain aging.
Complement Pathway Activation in
Neurodegenerative Disease
A number of chronic neurodegenerative diseases of the
central nervous system (CNS) are characterized by prominent
neuroinflammation marked by activated astrogliosis and
microgliosis. In AD and MS affections of CNS, similar to
what is seen in TBI, there is strong evidence of complement
involvement in the pathogenesis that arises from a confluence
of histochemical, genetic, and model data. The involvement
of the complement system in the AD process comes from the
identification of complement receptor 1, the C3b receptor
expressed on macrophage/erythrocyte or monocyte cells, as a
genetic risk to develop this neurodegenerative disease (Lambert
et al., 2009; Crehan et al., 2012). In fact, erythrocyte cells capture
complement-opsonized Aβ through CR1 receptor expressed
on their membrane and facilitate clearance mechanism, which
is relevant in AD pathophysiology (Brubaker et al., 2017).
On the other hand, Aβ deposition promotes complement
pathway activation by inhibition of CFI enzymatic activity, a
cofactor of CFH (Lashkari et al., 2018). Thus, accumulation
of Aβ contributes to increase C3 complement protein and
ends up giving rise to the anaphylactic C3a/C5a proteins and
MAC formation (Bradt et al., 1998; Lian et al., 2015). In fact,
accumulation of these complement proteins generates damaged
neurons, increases numbers of activated glial cells (Bradt et al.,
1998), and, through neuronal C3a/C3aR signaling, disrupts
dendritic morphology and network function (Lian et al., 2015).
The Aβ-induced neuroinflammation response is also exaggerated
by C5a/C5aR signaling (An et al., 2018), demonstrating another
link between Aβ and complement activation. Similarly, the role of
the complement pathway has been investigated in the context of
the neuroinflammatory autoimmune neurodegenerative disease
MS. Comparatively, these studies would help to understand
the potential role of complement pathways in the long-term
outcomes after TBI. With the aim to better understand the cause
of MS, a demyelinating and neurodegenerative disease of the
CNS, several investigations defined and quantified complement
compounds in the blood circulation and CSF. In relation to the
inflammatory activity of MS, to define potential biomarkers of
the various MS disease forms, levels of C3, C4, and C9 were
mostly investigated, providing convincing evidence of the role of
complement compounds in MS disease development. The data
obtained from various cohorts of patients, however, generated
controversies. Indeed, early studies in patients with progressive
MS revealed elevated levels of C4 in MS-serum and reduced
C4 levels in MS-CSF (Jans et al., 1984). These findings were,
however, not supported by others (Jongen et al., 2000). A more
recent study defined elevated plasma C4a levels and elevated
C3 levels in CSF of patients with active relapsing-remitting MS
(RRMS) potentially providing furthermore follow-up markers
for therapeutic efficacy (Tatomir et al., 2017). The levels of C9
compound and terminal complement complex (MAC) in CSF
and/or blood also give heterogeneous quantitative data found
to be reduced, unchanged, or increased (Ingram et al., 2009).
Differences in the presence of the complement compounds
in the CSF and blood circulation might be related to the
modulation of the BBB by the inflammatory disease activity
at the various disease MS forms. Histophathological post-
mortem investigations of MS brain tissues revealed complement
deposition and activation. Activated microglia is commonly
observed in contact with axons suffering from demyelination.
In brain tissue from patients with progressive MS, a combined
immunohistopathology and in situ hybridization study showed
the local expression of compounds of the complement activation
pathways. Both transcripts for C1qA, activation fragment
and opsonin C3b, and immunostained proteins C1q of the
classical complement pathway and the activation CFB-fragment
Bb of the alternative complement pathway were observed in
neurons and/or glia within and in the vicinity of cortical and
deep gray matter lesions. Furthermore, activated microglia
expressing complement anaphylatoxin receptor were observed
in these lesions in post-mortem brain tissue (Watkins et al.,
2016). The deposits of activated C3 fragment on microglia
in such chronic cortical lesions, but not in acute disease,
indicate that C3 could function as a mediator for the removal
of damaged nervous cells in the MS animal model of the
relapsing experimental autoimmune encephalomyelitis (EAE)
(Michailidou et al., 2017). The formation of MAC as a final
complement product has been reported in acute and chronic
white matter lesions of MS and would have a direct impact
on nervous tissue destruction (Compston et al., 1989; Storch
et al., 1998). Many experimental animal studies of MS support
the complement-mediated role of nervous tissue degeneration.
Further evidence for MAC in the inflammatory disease
progression is documented in the EAE mouse model by the
systemic curative administration ofMAC inhibitors that prevents
relapses after a first clinical attack (Michailidou et al., 2018).
In EAE gray matter neurodegeneration, a significant synapse
loss in the CA1 statum radiatum of the hippocampus reflecting
cognitive impairment is caused by increased complement
production and deposition of Cq1 and C3d that could make
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TABLE 1 | Summary of complement effects on the TBI process in animals models and human studies.
Human Complement analysis Complement levels References
Severe TBI C3/CFB ↑CSF Kossmann et al., 1997
Severe TBI C3/C1q/C4 ↑CSF Stahel et al., 1998
Severe TBI C5b9 ↑CSF Stahel et al., 2001
Severe TBI C3/C9 ↑Plasma Bao et al., 2018
Severe TBI MBL ↑Plasma Osthoff et al., 2017
Animal models Complement target Complement biologic effects References
Cortical impact (severe TBI) C9/CFB ↑Serum Thelin et al., 2018
Cortical contusion (severe TBI) C3 ↑Deposits (peri-lesion tissue) Bellander et al., 1996
Cortical contusion (severe TBI) C9 ↑Deposits (damaged neurons) Bellander et al., 1996
Intra-cerebral hemorrhage C3−/− mice ↓Brain edema
↓Microglia activation/infiltration
Sewell et al., 2004;
Yang et al., 2006
Severe TBI swine resuscitation CD59/C1q ↓Complement system activation associated to a decrease of
lesion size
Dekker et al., 2014a,b;
Bambakidis et al., 2016
Cortical impact (severe TBI) CD59−/− mice ↑Neuronal cell death Stahel et al., 2009
Severe closed head injury mice C6 antisense oligonucleotide
Or C5 convertase inhibition
↓C5b9 deposits/axon loss
↓Microglia/macrophage accumulation
↓Neuronal cells death
↑Neurologic perfomances
Fluiter et al., 2014
Cortical impact (severe TBI) C3 cleavage inhibition ↓Microglial/astrocyte activations
↓C3 deposits/neuron cells death
↑Cognitive/functional recovery
Rich et al., 2016;
Alawieh et al., 2018
Focal trauma (severe TBI) cfb−/− mice ↓Neuronal cell death Leinhase et al., 2006
Focal trauma (severe TBI) Anti-CFB antibody ↓Inflammation/cell death Leinhase et al., 2007
Cortical impact (severe TBI) C1q inhibitor ↓Cognitive dysfunction/contusion volumes Longhi et al., 2009
Cortical impact (severe TBI) MBL ↑MBL deposits (injured cortex) Longhi et al., 2014
Cortical impact (severe TBI) mbl−/− mice ↑Cortical cell death Longhi et al., 2014
CSF, CerebroSpinal Fluid; MBL, Mannose Binding Lectin protein.
synapses vulnerable to phagocytosis by microglia. In particular,
C3 mediates microglial activation and EAE motor impairments
(Hammond et al., 2019). Altogether, there is convincing evidence
that the complement activation is involved in MS disease
development and the cerebral complement over-activation in
inflammatory CNS lesions may be essential for the irreversible
progression of MS. The knowledge gathered on the role of the
complement pathway activation in MS patients and animal
model of MS can be useful for understanding the chronic brain
disorders post-TBI. The presence of the complement in serum
can serve as a biomarker in TBI patients, and the potential
inhibition of the complement can be a therapeutic strategy for
the long-term consequences of TBI.
CONCLUDING REMARKS
Complement pathway activation is present early after TBI and
can contribute to the development of the secondary injuries
by inducing neuronal cell loss and synapse pruning (Table 1).
Very likely, the complement activation is still present in the
long term after TBI (Table 1). The knowledge on complement
activation in AD and MS strongly suggests that the activation
of the complement pathways in the long term after TBI
could be an interesting mechanism in order to develop new
therapeutic approaches for chronic TBI. It is possible that
the pruning of synapses by complement-mediated microglia
activation causes long-term neurological handicaps including
cognitive impairment in various models of neurodegenerative
diseases such as Alzheimer’s disease, viral encephalitis, TBI,
and MS and potentially contributes to schizophrenia (Stevens
et al., 2007; Paolicelli et al., 2011; Ingram et al., 2014; Hong
et al., 2016; Sekar et al., 2016; Vasek et al., 2016; Alawieh
et al., 2018; Hammond et al., 2019). Therefore, inhibition
of the long-term complement activation could improve
TBI outcomes.
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